Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

954
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
954
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

797
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
797
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drug Therapy01:28

Drug Therapy

236
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
236
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease activity and maternal-fetal outcomes in pregnant women with cushing's syndrome: a systematic review and meta‑analysis.

Reviews in endocrine & metabolic disorders·2026
Same author

A new and useful tool for differentiating prolactinomas from non-functioning pituitary adenomas: a pilot study of the cabergoline disconnection test.

Einstein (Sao Paulo, Brazil)·2025
Same author

Combination of sibutramine and topiramate for the treatment of obesity: the SIBAMATE retrospective cohort study : Sibutramine and topiramate for the treatment of obesity.

Diabetology & metabolic syndrome·2025
Same author

Ectopic GHRH production: revisiting a rare cause of acromegaly.

Reviews in endocrine & metabolic disorders·2025
Same author

Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery.

Reviews in endocrine & metabolic disorders·2025
Same author

Expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and their relationship with cavernous sinus invasion.

Endocrine oncology (Bristol, England)·2025
Same journal

Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Is diagnosis of Cushing's disease moving beyond Bilateral inferior petrosal sinus sampling?

The Journal of clinical endocrinology and metabolism·2026
Same journal

Can Machine Learning Transform the Diagnostic Approach to Congenital Disorders of Adrenal Steroidogenesis?

The Journal of clinical endocrinology and metabolism·2026
Same journal

Children's neurodevelopment at school age after hysterosalpingography with iodinated contrast: a cohort study.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Bone phenotype of patients with genetic forms of lipodystrophy: a systematic review of literature.

The Journal of clinical endocrinology and metabolism·2026
Same journal

The Extra X Chromosome and Autoimmune Susceptibility in Klinefelter Syndrome.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.5K

Approach to the Patient With Dopamine-Resistant Microprolactinoma.

Andrea Glezer1, Matheo Augusto Morandi Stumpf1, Nara Lima Queiroz1

  • 1Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo 05403-010, Brazil.

The Journal of Clinical Endocrinology and Metabolism
|November 14, 2025
PubMed
Summary
This summary is machine-generated.

Prolactinomas, common pituitary tumors causing hyperprolactinemia, affect women of reproductive age. Management varies, but dopamine agonist resistance presents challenges, necessitating further research for new treatments.

Keywords:
cabergolinedopamine agonisthyperprolactinemiamicroprolactinomaneurosurgerypregnancy

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.3K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

613

Related Experiment Videos

Last Updated: Jan 11, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

19.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.3K
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

613

Area of Science:

  • Endocrinology
  • Oncology
  • Reproductive Medicine

Background:

  • Prolactinoma is the most common pituitary tumor, leading to hyperprolactinemia, particularly in women of fertile age.
  • Clinical manifestations include galactorrhea, menstrual irregularities, and infertility.
  • Microprolactinomas are prevalent, with management strategies tailored to menopausal status, symptoms, and fertility desires.

Purpose of the Study:

  • To review the management of prolactinomas, focusing on treatment strategies for different patient populations.
  • To explore the phenomenon of dopamine agonist (DA) resistance in prolactinoma treatment.
  • To discuss the broader implications of hyperprolactinemia on metabolic health, bone density, and cancer risk.

Main Methods:

  • Literature review of prolactinoma management and dopamine agonist resistance.
  • Analysis of clinical presentation, diagnostic criteria, and therapeutic options.
  • Discussion of potential mechanisms and clinical concerns related to DA resistance.

Main Results:

  • Management options include expectant management, oral contraceptives, dopamine agonists, and surgery.
  • Dopamine agonist resistance affects less than 10% of cases, with reduced D2R expression being a primary suspected cause.
  • Concerns in resistant cases include tumor growth during assisted reproduction and pregnancy.

Conclusions:

  • Understanding dopamine agonist resistance mechanisms is crucial for developing novel therapeutic strategies.
  • Hyperprolactinemia's impact on metabolic parameters, osteoporosis, and breast cancer risk warrants consideration.
  • Further research into DA resistance is needed to improve treatment outcomes for prolactinoma patients.